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Intellectual disability (ID) is a highly heterogeneous disorder involving at least 600 genes, yet a genetic diagnosis remains elusive in
~35%–40% of individuals with moderate to severe ID. Recent meta-analyses statistically analyzing de novo mutations in >7,000 indi-
viduals with neurodevelopmental disorders highlighted mutations in PPM1D as a possible cause of ID. PPM1D is a type 2C phosphatase
that functions as a negative regulator of cellular stress-response pathways by mediating a feedback loop of p38-p53 signaling, thereby
contributing to growth inhibition and suppression of stress-induced apoptosis. We identified 14 individuals with mild to severe ID
and/or developmental delay and de novo truncating PPM1D mutations. Additionally, deep phenotyping revealed overlapping behav-
ioral problems (ASD, ADHD, and anxiety disorders), hypotonia, broad-based gait, facial dysmorphisms, and periods of fever and vom-
iting. PPM1D is expressed during fetal brain development and in the adult brain. All mutations were located in the last or penultimate
exon, suggesting escape from nonsense-mediated mRNA decay. Both PPM1D expression analysis and cDNA sequencing in EBV LCLs of
individuals support the presence of a stable truncated transcript, consistent with this hypothesis. Exposure of cells derived from indi-
viduals with PPM1D truncating mutations to ionizing radiation resulted in normal p53 activation, suggesting that p53 signaling is
unaffected. However, a cell-growth disadvantage was observed, suggesting a possible effect on the stress-response pathway. Thus, we
show that de novo truncating PPM1D mutations in the last and penultimate exons cause syndromic ID, which provides additional
insight into the role of cell-cycle checkpoint genes in neurodevelopmental disorders.Next-generation sequencing (NGS) techniques have accel-
erated the discovery of genes associated with intellectual
disability (ID).1–7 Mutations in more than 600 autosomal
and X-linked genes have been implicated,8 but many
more are likely to be elucidated. Recently, two separate
meta-analyses used the de novo mutations identified
in >7,000 individuals affected by a neurodevelopmental
disorder to identify mutations that might also cause
ID.9,10 In both meta-analyses, PPM1D (protein phos-
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GeneMatcher.9–12 One individual was previously described
as part of the Simons Simplex Collection cohort.13 Herein,
we report on an ID syndrome caused by de novo germline
mutations in the last and penultimate exons of PPM1D, as
well as the implication of such mutations in the role of
PPM1D in stress responses.
We collected clinical data by inviting individuals back to
the clinic for re-evaluation and deep phenotyping.
Detailed clinical information of the 14 individuals
(2–21 years old) is described in the Supplemental Note
and summarized in Table 1. All but one individual had
mild to severe ID (93%), and 11 individuals (79%) had
behavioral problems, such as anxiety disorders, attention
deficit hyperactivity disorder (ADHD), obsessive behavior,
sensory integration problems, and autism spectrum disor-
der (ASD). The individual with a normal IQ of 96 did, how-
ever, need extra tutoring at school and showed an anxiety
disorder and attention problems. Seven individuals were
hypersensitive for sounds. Hypotonia was a common
feature in the individuals for whom this information was
available (10/14 [71%]), and several individuals had a
broad-based gait (5/10 [50%]). Brain MRI was performed
for nine individuals (64%) without any substantial find-
ings, except for moderate cortical and cerebellar atrophy
and abnormal vascular structures in individual 13, who
was also diagnosed with Potocki-Shaffer syndrome. Eight
individuals (62%) had short stature, but weight and head
circumference were variable. Feeding difficulties were a
common feature (10/14 [71%]), and remarkably, eight in-
dividuals (62%) had periods of illness with fever and/or
vomiting. In addition, nine individuals had a high pain
threshold (90%). One individual had problems emerging
from anesthesia. Vision problems, such as myopia, hyper-
metropia, and strabismus, were seen in nine individuals
(64%). There was no apparent shared or consistent facial
gestalt despite the presence of overlapping facial features,
including a broad forehead, low-set posteriorly rotated
ears, upturned nose, and broad mouth with thin upper
lip (Figure 1A). Ten individuals (91%) had small hands
often with brachydactyly, seven individuals had small
feet, and six individuals had hypoplastic toenails. To
further delineate the clinical spectrum associated with
de novo mutations in PPM1D, we established a website
to collect detailed clinical information of additional indi-
viduals to be identified over the coming year (see Web
Resources).
Whole-exome sequencing was performed in all individ-
uals as previously described,9,10 and all were identified to
have a deleterious PPM1D mutation. This study was
approved by the institutional review board Commissie
Mensgebonden Onderzoek Regio Arnhem-Nijmegen
NL36191.091.11 and received UK research ethics commit-
tee (REC) approval (10/H0305/83 granted by the Cam-
bridge South REC and GEN/284/12 granted by the
Republic of Ireland REC). Written informed consent was
obtained from all individuals. Subsequent confirmation
by Sanger sequencing and investigation of parental DNAsamples of 13 individuals indicated that PPM1Dmutations
had occurred de novo. Interestingly, all 14 ID-associated
PPM1D mutations are located in the last and penultimate
exons (Figure 1B) and are predicted to result in a premature
stop codon in exon 6 or in the last 55 nucleotides of exon 5
(Figure 1C). The truncated mRNA is therefore presumed to
escape nonsense-mediated decay (NMD) and result in a
truncated PPM1D still containing its functional protein
phosphatase Mg2þ/Mn2þ-dependent (PPM)-type phospha-
tase domain but lacking its nuclear localization signal
(NLS). To analyze PPM1D mRNA expression on cDNA
derived from lymphoblastoid cell lines (LCLs) of individ-
uals with a mutation in PPM1D, we obtained LCLs from
human blood by immortalization via Epstein-Barr virus
(EBV) transformation according to standard procedures.
PPM1D mRNA expression analysis using two different
sets of primer pairs showed no significant difference in
mRNA levels between control lines and cDNA derived
from LCLs of individuals 2 and 3, indeed confirming that
the truncatedmRNAwas not subjected toNMD (Figure 2B).
Subsequent Sanger sequencing, performed in four individ-
uals (1–3 and 7) with a primer set targeting the mutated
area (PPM1D_1 and PPM1D_3), confirmed the presence
of truncated PPM1D transcripts. We showed that the
de novo mutations in PPM1D lead to stable transcription
of truncated mRNAwith normal expression levels. Because
the truncated protein lacks its NLS, it might no longer
reach the nucleus to exert its function. Immunohisto-
chemical staining of PPM1D showed cytosolic and nuclear
staining in LCLs in a control line (Figure S1). Similar stain-
ing in EBV-transformed LCLs from an individual with a
heterozygous de novo mutation in PPM1D showed a
similar localization (Figure S1). However, the latter can be
explained by the presence of the wild-type allele, which
still results in a fully functional PPM1D. Notably, given
the specific need of PPM1D in cellular stress, it is possible
that localization of the mutant PPM1D is mostly affected
during this state. Further quantification of PPM1D in
the different cell compartments and under different phys-
iological scenarios could help to improve our understand-
ing of the biological mechanism underlying PPM1D
pathology.
Importantly, de novo mutations in PPM1D have not
been observed in over 2,000 control trios.1,15–18 Interroga-
tion of large databases, such as the Exome Aggregation
Consortium (ExAC) Browser, shows that PPM1D is under
constraint for missense mutations (Z score 3.13). Interest-
ingly, however, PPM1D seems to be tolerant of loss-of-
function mutations (with pLI ¼ 0.00).19 Together, these
scores could indicate that the pathophysiological mecha-
nism underlying ID-associated PPM1D mutations is more
complex and that a mechanism involving a C-terminally
truncated protein is more disruptive than complete loss
of it, similar to what has been identified for DVL1
and DVL3 frameshift mutations causing Robinow syn-
drome.20–22 This highlights the importance of not disre-
garding these genes without consideration, given that
Table 1. Main Clinical Features of Affected Individuals
Individual
Total1 2 3 4 5 6 7 8 9 10 11 12 13 14
General Information
Age 14 y 5 y 5 y 2 y 5 y 10 y 9 y, 9 m 21 y 16 y 6 y 18 y 15 y 7 y 7 y 2–21 y
Gender F M F M M M M M F F M F F F 7 M, 6 F
Mutation c.1221T>A
(p.Cys407*)
c.1216del
(p.Thr406
Profs*3)
c.1260þ
1dup
(p.Ser421
Thrfs*12)
c.1210C>T
(p.Gln404*)
c.1269_
1270dup
(p.Glu424
Glyfs*8)
c.1339G>T
(p.Glu447*)
c.1188_
1191del
(p.Asp397
Alafs*11)
c.1250dup
(p.Pro418
Thrfs*16)
c.1270dup
(p.Glu424
Glyfs*10)
c.1270dup
(p.Glu424
Glyfs*10)
c.1281G>A
(p.Trp427*)
c.1281G>A
(p.Trp427*)
c.1654C>T
(p.Arg552*)
c.1404_
1411del
(p.Lys469
Argfs*4)
NA
Inheritance de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo NKa de novo NA
Growth
Birthweight (g) 2,780 4,000 2,655 3,742 3,527 3,180 2,200 2,211 3,061 2,730 3,200 3,429 NK 3,140 NA
Height (SD) 2.7 1.5 2.8 0 NK 3 <3 <2.5 2.3 2.5 2.7 þ0.41 2.6 2 NA
Weight (SD) þ2.3 þ0.5 1.9 0 NK þ2 þ0.5 <2.5 2.2 2 1.8 >þ2.5 4.9 0 NA
Head
circumference
(SD)
þ0.7 0.5 1.5 0.5 0.5 1 1.8 <2.5 3.1 2.5 2.5 þ3.49 NK 1.5 NA
Neurological
ID (severity) þ (mild to
moderate)
þ (mild to
moderate)
þ (mild) þ þ b þ (mild to
moderate)
þ (mild to
moderate)
þ (severe) þ (moderate) þ (moderate) þ (severe) þ (severe) þ (mild) 13/14 (93%)
Hypotonia þ þ þ þ þ   þ þ þ þ  þ  10/14 (71%)
Broad-based gait þ NK þ þ þ    þ NK NK  NK  5/10 (50%)
Sensitivity to
sounds
NK NK þ þ NK NK þ þ þ þ NK NK NK þ 7/7 (100%)
Behavioral
features
ADHD,
ODD,
anxiety
disorder
sensory
integration
problems
short
attention,
panic
attacks
sensory
integration
problems,
hyperarousal,
short
attention
 anxiety
disorder,
attention
difficulties,
biting
sensory
integration
problems,
anxiety,
short
attention
anxiety ASD   ASD,
attention
problems,
oppositional,
aggression
ASD ASD 11/14 (79%)
Facial
Broad forehead þ þ   NK   þ þ þ þ NK þ þ 8/12 (67%)
Low-set,
posteriorly
rotated ears
þ þ þ þ (right) NK NK   þ þ þ NK NK þ (only
posteriorly
rotated)
8/10 (80%)
Upturned
nose
þ  þ  NK     þ þ NK þ  5/12 (42%)
Thin upper lip  þ þ þ NK þ  þ þ þ þ NK þ þ 10/12 83%
Broad mouth þ þ þ  NK þ   þ  þ NK   6/12 50%
(Continued on next page)
Table 1. Continued
Individual
Total1 2 3 4 5 6 7 8 9 10 11 12 13 14
Gastrointestinal
Feeding
difficulty
þ (neonatal) þ (neonatal) þ (neonatal) þ þ  þ þ   þ  þ þ (neonatal) 10/14 (71%)
GER and/or
vomiting
þ þ þ þ NK þ þ þ (infancy) þ þ   þ  10/13 (77%)
Constipation  þ  þ þ  þ þ (infancy) þ  NK  þ þ 8/13 (55%)
Skeletal
Small hands NK þ þ  NK þ þ þ þ þ þ NK þ þ 10/11 (91%)
Small feet NK NK þ  NK NK þ þ þ NK þ NK þ þ 7/8 (88%)
Hyperlordosis þ    þ NK þ þ þ NK þ NK NK þ 7/10 (70%)
Other
Periodic
illnessc
þ þ   þ þ þ þ þ þ   NK  8/13 (62%)
High pain
threshold
NK þ þ þ NK þ þ þ þ þ þ NK NK  9/10 (90%)
Congenital
abnormalities
bicuspid
aortic valve
retractile
testes,
small
genital
small VSD
and small
ODA
 bilateral
cryptor-
chidism
    laryngo-
malacia
  bilateral
parietal
foramina,
exostoses,
diaphragmatic
hernia,
volvulus
intestined
 6/14 (43%)
Vision
problems
myopia,
nystagmus,
amblyopia
hyper-
metropia,
cilinder,
strabismus
hyper-
metropia
myopia,
strabismus,
astigmatism,
CVI
  hyper-
metropia,
strabismus,
astigmatism,
nystagmus
myopia,
strabismus
 hyper-
metropia,
strabismus
hyper-
metropia,
strabismus
 strabismus,
nystagmus,
iridocyclitis,
retinal
detachment
 9/14 (64%)
Hypoplastic
nails
þ (toenails) þ (toenails) þ (toenails)  þ (toenails)   þ (fifth
toenails)
  þ NK NK  6/12 (50%)
Recurrent
infections
  NK  NK NK þ NK þ NK þ þ þ  5/9 (56%)
Abbreviations are as follows: þ, present; , absent; y, years; m, months; M, male; F, female; NK, not known; ID, intellectual disability; ADHD, attention deficit hyperactivity disorder; ODD, oppositional defiant disorder; ASD,
autism spectrum disorder; GER, gastro esophageal reflux; VSD, ventricle septum defect; ODA, open ductus arteriosus; and CVI, cerebral visual impairment.
aParental DNA not available.
bIndividual did have learning difficulties.
cIncluding cyclic vomiting.
dIndividual 13 also had a confirmed diagnosis of Potocki-Shaffer syndrome.
Figure 1. Photographs of Nine Individuals with a Truncating Mutation in PPM1D, De Novo Mutations in PPM1D, and Predicted
Consequences at the Protein Level
(A) Shared facial features including a broad forehead, upturned nose, broad mouth with thin upper lip, and low-set posteriorly rotated
ears. Extremities show small hands and feet with brachydactyly and hypoplastic toenails. Individual 13 also had a confirmed diagnosis of
Potocki-Shaffer syndrome. Parents provided informed consent for the publication of these photographs.
(B) Schematic representation of the coding sequence of PPM1D (GenBank: NM_003620.3), including zoomed-in exons 5 and 6. All de
novo PPM1Dmutations identified are depicted according to their location in the coding sequence. Protein domain structures encoded by
exons 5 and 6 are highlighted in color: red for the PPM-type phosphatase domain (in exon 5) and green for the nuclear localization signal
(in exon 6).
(C) Predicted protein sequences in individuals 1–14. The last part of the translated sequence of exon 5 is in blue, and the amino acids
encoded by the first part of exon 6 are in orange. For individuals 1–14, the predicted mutant amino acids are depicted in red. Abbrevi-
ations are as follows: WT, wild-type; and aa, amino acid.the disease-causing mutations could have other patho-
physiological mechanisms not directly inferable from
such metrics in the ExAC Browser.PPM1D has previously been shown to be expressed in
both mouse and human brain,23,24 but a second hint
toward a role for PPM1D in the occurrence of ID would
AC D
B
Figure 2. Functional Effects of PPM1DMutations at the RNA and Protein Levels and Downstream Effects on p53 Activation and Cell
Growth
(A) Semiquantitative PCR using primers PPM1D_3 (forward: 50-AACCTGACTGACAGCCCTTC-30; reverse: 50-ACCAGGGCAGGTA
TATGGTC-30) on tissue-specific cDNA libraries shows PPM1D expression in fetal and adult brain. EBV-LCL cDNA is the positive control
(þ), and ddH2O is the negative control ().
(B) Expression levels of PPM1Dwere quantified by qPCR using cDNA obtained from EBV-LCLs derived from individuals with a mutation
in PPM1D (individuals 2 and 3). Experiments were performed in triplicate with two sets of primer pairs: PPM1D_1 (forward: 50-TGC
TTGTGAATCGAGCATTG-30; reverse: 50-CCCTGATTGTCCACTTCTGG-30) and PPM1D_2 (forward: 50-AAGTCGAAGTAGTGGTGCT
CAG-30; reverse: 50-TCTTCTGGCCCCTAAGTCTG-30). Analysis was performed with SDS software according to standard procedures,
and GUSB expression was used as a calibrator (forward: 50-AGAGTGGTGCTGAGGATTGG-30; reverse: 50-CCCTCATGCTCTAGC
GTGTC-30).14 There was no significant change in PPM1D mRNA expression between affected individuals and control lines. Abbrevia-
tions are as follows: n.s., not significant; Ind, individual; Con, control individual; and Avg, average. Results are presented as the
average5 SD.
(C) Radiation-induced activation of p53 was investigated in fibroblasts derived from individual 1, EBV-LCLs derived from individuals 2
and 3, healthy control cells, and the cancer cell line with active PPM1D (MCF7 as the positive control). Cells were exposed to gamma
irradiation (5 Gy) from an X-ray source. Whole-cell lysates were generated from cells 30–60 min and 4 hr after irradiation and subjected
to protein electrophoresis. Immunoblotting of electrophoresed lysates was performed with antibodies specific to p53 (9282S), phospho-
Histone gH2AX (ser139) (9718S), and actin (I-19), or b-tubulin (D-10). Anti-rabbit, anti-mouse, and anti-rabbit secondary antibodies
were incubated with the blot (1:5,000) for 1 hr at room temperature, and then exposure using enhanced chemiluminescent detection
followed. Western blot analysis showed no difference between case and control cell lines but did show increased p53 activation in the
PPM1D mutant breast cancer cell line MCF7.
(D) Growth behavior of EBV-LCLs derived from individuals with a mutation in PPM1D (individuals 2 and 3) was compared with that of
age- and sex-matched control EBV-LCLs. Cells were irradiated (UV light: 60 J/m2) and cultured in a concentration of 3 3 105 cells/mL.
Cell numbers were counted in triplicate after 48 hr, and the experiment was repeated three times. 48 hr after irradiation, the number of
EBV-LCLs derived from individuals with a mutation in PPM1D (n ¼ 2) was significantly lower than that of control cells (n ¼ 2), whereas
the growth of untreated cells was unaffected. Abbreviations are as follows: *, p< 0.05; n.s., no significance; Ind, individual; Con, control
individual; and Avg, average. Results are presented as the average5 SD.be its expression in the developing brain. We therefore
investigated PPM1D expression in cDNA libraries obtained
from fetal and adult brain by using semiquantitative PCR.
Human cDNA libraries from different human tissues were
purchased from Stratagene. Expression of PPM1D in em-
bryonic and adult brain and EBV-LCLs (positive control)
was investigated with PPM1D-transcript-specific semi-
quantitative PCR using the primer set PPM1D_3. We de-tected PPM1D expression in both fetal and adult brain
(Figure 2A). In addition, our analysis showed wider fetal
(developmental), whereby PPM1D expression was detected
in fetal liver and skeletal muscle, but not in their adult
counterparts (data not shown). The expression of PPM1D
in the fetal brain suggests a role during fetal brain develop-
ment and thus potentially in developing normal cogni-
tion. Although we were not able to further narrow down
the expression to detailed brain regions, the highest Ppm1d
expression in mice has been reported in the cerebellum,23
which is the center for coordination. Several of our affected
individuals had a broad-based gait, a possible sign of cere-
bellar disturbance, which might therefore be associated
with the mutation in PPM1D. However, the individuals
did not display other symptoms of coordination defects,
and in the individuals who had received brain MRI,
no structural abnormalities of the cerebellum could be
identified.
PPM1D has also been reported to be an important regu-
lator of global heterochromatin silencing and thus critical
in maintaining genome integrity.25 The latter was exam-
ined in germ cells of Ppm1d-deficient mice, which showed
enlarged heterochromatin centers with enriched immuno-
fluorescent staining for H3K9me3 and HP1g, both markers
for transcriptional repression.25 When PPM1D dysfunc-
tion indeed alters gene expression, this might have an
effect on fetal (brain) development. Moreover, Ppm1d-defi-
cient mice show an increase in anxiety and depression-like
behavior,26 suggesting a potential protective function of
PPM1D in mood stabilization.26 Interestingly, four of the
individuals with a PPM1D mutation showed anxiety.
PPM1D (also known asWip1) is, like other genes encod-
ing PPM and PP2C phosphatases, a regulator of stress
response.27 In particular, PPM1D regulates the DNA dam-
age response (DDR) pathway by inhibiting p53 and other
tumor suppressors (p38, ATM, Chk1, and Chk2) through
dephosphorylation of these proteins.27 Previously substan-
tial amounts of work have gone into the role of PPM1D in
tumorigenesis, given that acquired PPM1Dmutations have
been identified in individuals with breast, ovarian, colon,
and lung cancer and are postulated to exert their effect
through gain of function.27–31 However, these mosaic
mutations in lymphocytes were shown to occur only in
individuals who had undergone chemotherapy and were
shown to be absent in DNA isolated from the germline
prior to chemotherapy.27–31 The gain-of-function effect
was shown by overexpression of cancer-associated
PPM1D mutations in tumor cells, which suppressed
ionizing radiation (IR)-induced molecular responses.28 In
normal conditions, exposure to IR causes upregulation of
p53 levels and phosphorylation of the histone H2AX
(gH2AX), events that are normally prevented by PPM1D
activity. In tumor cells with overexpression of cancer-asso-
ciated PPM1D mutations, p53 and gH2AX upregulation
after IR exposure is impaired, suggesting that in tumor
cells, truncating PPM1D mutations are hyperactive.28 We
tested the upregulation of p53 and gH2AX in MCF7 cells,
a breast cancer cell line serving as a positive control, which
showed the expected upregulation of p53 and gH2AX, sug-
gesting that the IR exposure was successful (Figure 2C).
Compared with healthy control cells, fibroblasts from indi-
vidual 1 and EBV-LCLs derived from individuals 2 and 3
showed normal p53 and gH2AX responses (Figure 2C). In
conclusion, these data indicate that ID-associated PPM1D
mutations do not cause p53 depletion, which suggests apathophysiological mechanism different from the ac-
quired PPM1D cancer-associated mutations.
As a regulator of the DDR, PPM1D plays an important
role in cell-cycle control by positively upregulating G1-
to-S phase progression.32 We hypothesized that the ID-
associated mutations in PPM1D would lose this positive
upregulation and thereby cause cells to stall in the
G1-to-S phase, leading to reduced cell proliferation. We
therefore next tested whether EBV-LCLs derived from indi-
viduals 2 and 3 showed growth abnormalities in compari-
son with age- and sex-matched control EBV-LCLs. For this,
cells were exposed to IR and analyzed for growth character-
istics (Figure 2D). Indeed, cells derived from individuals
showed 50% less growth than control lines, whereas the
growth of untreated cells was unaffected (Figure 2D),
showing that heterozygous PPM1D truncation leads to
growth disadvantage after radiation. Hence, if the effect
of the truncating mutations in our cases is a gain of func-
tion, this does not seem to affect the role of PPM1D on
p53. However, a cell-growth disadvantage was observed
after IR, suggesting that another function related to
PPM1D cell-cycle checkpoints might be compromised.
Several genes are known to have somatic mutations that
lead to cancer but germline mutations that cause an ID
phenotype. Examples include genes encoding compo-
nents of the RAS-MAPK pathway, SETBP1 (SET binding
protein 1 [MIM: 611060]), and CTNNB1 (catenin beta 1
[MIM: 116806]).33–36 Also, some of these germline muta-
tions give rise to a higher cancer risk, whereas others do
not.33–36 Germline PPM1D mutations in individuals with
cancer have to our knowledge not yet been reported.
Although it is known that germline mutations in
some genes, for instance NF1 (neurofibromin 1 [MIM:
613113]), cause ID and a higher risk of (benign)
tumors,37 none of the individuals studied here (2–21 years
old) have developed cancer. Thus, we cannot exclude nor
confirm the possibility that the PPM1D mutations in the
individuals with ID predispose to cancer.
In conclusion, de novo truncating germline mutations
in the last and penultimate exons of PPM1D lead to an
ID syndrome with behavioral problems, hypotonia,
broad-based gait, periods of fever and vomiting, high
pain threshold, short stature, small hands and feet, and
overlapping facial dysmorphisms. Exposure of affected
cells to IR resulted in normal p53 activation, suggesting
that p53 signaling is not affected by the truncated protein.
Nonetheless, a cell-growth disadvantage after IR was
observed. The significant enrichment of de novo muta-
tions in individuals with ID, the expression in the devel-
oping and mature brain, and this clinical ID syndrome
underscore the role of PPM1D in neurodevelopment.Supplemental Data
Supplemental Data include a Supplemental Note and one figure
and can be found with this article online at http://dx.doi.org/10.
1016/j.ajhg.2017.02.005.
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